Insulet appoints new CEO as Hollingshead steps down

ACTON, Mass. – Insulet has appointed Ashley McEvoy as president and CEO effective immediately.  

She succeeds Jim Hollingshead, who has agreed to end his employment at the company and resign from its board of directors.  

“Insulet continues to successfully deliver on its financial, clinical and operational objectives while advancing its mission to improve the lives of people with diabetes, and we are confident this leadership change will further the company’s success,” said Timothy Scannell, chairman of Insulet’s board of directors. “Having stepped into the CEO role from the board of directors, Jim has led Insulet through a very strong period of growth and development. We’re grateful for his contributions, and we wish him the best in his future endeavors.” 

Hollingshead, who joined Insulet in 2022, previously served as president of Resmed’s Sleep and Respiratory Care business. 

McEvoy has previously held roles as executive vice president and worldwide chairman of Johnson & Johnson’s MedTech business. She has deep diabetes experience, having previously served as group chairman of Johnson & Johnson Vision and Diabetes Care.  

“Insulet has transformed diabetes care, and I am honored to join the company as its next CEO,” said McEvoy. “Insulet has massive, untapped growth potential, a talented team, unparalleled pharmacy channel access and manufacturing capabilities, and deeply loyal customers – remarkable differentiators and a strong foundation for continued success. At this critical moment in the company and market’s evolution, Insulet has a unique opportunity to enhance innovation, drive global expansion, and win the hearts and minds of more providers and consumers by thinking differently about the experiences and needs of people with diabetes.”